Review of the Institute of Infection and Immunity (III) – Management Response Action Plan (MRAP)
Evaluation: Institute of Infection and Immunity
Evaluation completed: 2017/18
Evaluation lead: CIHR
| Recommendation | Response (Agree/Disagree) |
Management Action Plan | Responsibility | Timeline |
|---|---|---|---|---|
| 1. The Panel recommends that the Institute of Infection and Immunity (III) continue with its current mandate. | Agree | Maintain III mandate | Governing Council | 2018/19 (Complete) |
| 2. The Panel recommends that III continue to lead on emerging threats, Anti-Microbial Resistance (AMR), and HIV/AIDS initiatives. | Agree | III to continue to be the lead institute on emerging threats, AMR, and HIV/AIDS and maintain each as strategic research priorities | Scientific Director, Institute of infection and Immunity in collaboration with the Vice-President, Research, Programs | 2018/19 (Complete) |
| 3. The Panel recommends hiring an Assistant Director, whose area of expertise complements that of the next SD. | Agree | Assistant Director with complementary skills to the Scientific Director will be hired | Scientific Director, Institute of infection and Immunity | 2018/19 (Complete) |
| 4. The Panel recommends that the next Scientific Director have the opportunity to select some of the members of the new Institute Advisory Board. | Agree | Consistent with regular practice, III’s new SD will select new members of IAB (with approval by Governing Council) | Scientific Director, Institute of infection and Immunity Governing Council to approve. |
2018/19 (Complete) |
| 5. The Panel recommends the next Scientific Director target communication and outreach activities to mid-career investigators to raise awareness of III’s role and funding mechanisms, and facilitate discussion around creating innovative funding structures. | Agree | Develop communication strategy to highlight III’s role and methods of support (including support for mid-career investigators) | Scientific Director, Institute of infection and Immunity in collaboration with the Executive Vice-President, Governance and External Relations and Vice-President, Research Programs | 2018/19 |
| 6. The Panel recommends that the next Scientific Director, as part of the strategic planning process, assess previous funding opportunities to identify, prioritize, and target future funding opportunities. | Agree | Assessment of previous funding to be incorporated into planning process during development of new strategic plan | Scientific Director, Institute of infection and Immunity in collaboration with the Vice-President, Research, Programs | 2019/20 |
- Date modified: